Navigation Links
MDS researchers join forces to advance patient treatments and outcomes

NEW YORK (June 18, 2012) NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium. The Consortium's mission is to significantly advance treatments and patient outcomes for Myelodysplastic Syndromes (MDS) through innovative research and clinical trials.

The five-year, $16 million multi-institution initiative is the first privately funded MDS research consortium in the United States. It is sponsored by the Aplastic Anemia & MDS International Foundation of Rockville, Md., and supported by the Edward P. Evans Foundation. The Consortium's funding to Weill Cornell Medical College will support MDS research at NewYork-Presbyterian/Weill Cornell Medical Center.

MDS is a cancer of bone marrow stem cells that inhibits the body's ability to produce healthy blood cells. The disease can be treated and, in some cases, controlled, but currently, the only cure is stem cell transplantation. The new Consortium will help fill a major gap in the United States for MDS-related clinical research by joining dedicated academic medical centers with a high volume of MDS patients, an established database of current and former patients and a significant track record of participation in MDS clinical trials. The collaboration will facilitate evaluation of promising new compounds, epidemiological studies and translational research studies leading to new classifications, treatments and procedures for MDS.

"MDS is an under-recognized disease. Sometimes we don't know why a patient has developed MDS, but we do know that those who have been exposed to cancer chemotherapy and radiation therapy are at increased risk," says Dr. Gail J. Roboz, Weill Cornell Medical College's principal investigator for the Consortium and director of the Leukemia Program at NewYork-Presbyterian/Weill Cornell Medical Center. "This Consortium offers a wonderful opportunity to develop new therapies and also to profile patients using the latest, state-of-the-art technologies so we can start to understand who gets MDS and why."

Other Consortium partners include the Cleveland Clinic's Taussig Cancer Institute, Dana-Farber Cancer Institute, MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

"One of the greatest challenges in research of rare diseases like MDS is having enough patients to conduct meaningful clinical trials. No single center can do it alone. This uniquely collaborative effort overcomes that barrier," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "To have these six leading MDS research centers working together in this way is unprecedented," Huber added. The Aplastic Anemia & MDS International Foundation will expand its programs for MDS patients, their families, and caregivers and local physicians who support and complement the aims and purposes of the Consortium.

"We are extremely pleased to work in partnership with AA&MDSIF and these six outstanding Consortium members. This collaborative endeavor reflects Mr. Evans' desire to support the highest quality MDS research, which will lead to improved treatments for patients and, ultimately, to finding a cure," said an Evans Foundation trustee.


Contact: Lauren Woods
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

Related medicine news :

1. Stanford researchers discover the African cichlids noisy courtship ritual
2. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
3. UCI researchers create mosquitoes incapable of transmitting malaria
4. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
5. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
6. VCU researchers identify changes in cholesterol metabolic pathways
7. An important breakthrough in immunology by IRCM researchers
8. Mount Sinai researchers develop a multi-target approach to treating tumors
9. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
10. Researchers at IRB Barcelona uncover new clues about the origin of cancer
11. HIV drug may slow down metastatic breast cancer, say researchers at Jeffersons Kimmel Cancer Center
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... private messaging application, announced today a significant contract that will provide its award-winning ... plans to build on the growing success of its Relay program, IBX Wire™, ...
(Date:10/13/2015)... ... 13, 2015 , ... e-con Systems Inc., a leading embedded design services company ... industry’s first RGB-IR pixel format camera with a USB 3.0 interface and e-CAM40_CUMI4682_MOD, ... of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a 4-megapixel ...
(Date:10/13/2015)... , ... October 13, 2015 , ... A child without ... why SmileCareClub , the leading remote invisible aligner system, has joined with ... otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate one ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... targets the unique health needs of new moms. Postnatal Omega-3, which has ... ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This breakthrough ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... LA JOLLA, Calif. , Oct. 13, 2015 /PRNewswire/ ... to revolutionize the practice of medicine, announced today the ... powered clinical research project that has the potential to ... San Diego, CA , at HLI,s ... open in 2016 in other US and International cities. ...
(Date:10/13/2015)... PARK, Calif. , Oct. 13, 2015 /PRNewswire/ ... of up to $100 million over five years ... Diseases (NIAID), part of the National Institutes of ... or treat acute or delayed effects of radiation ... , a division of SRI International will provide ...
(Date:10/13/2015)... MILFORD, Mass. , Oct. 13, 2015  SeraCare ... diagnostics manufacturers, announced today that the company,s precision medicine ... growing line of reference materials for next-generation sequencing (NGS)-based ... Mutation Mix-I (AF1-10) contains the same mixture of mutations ... the previously launched AF20 mix , but is ...
Breaking Medicine Technology: